Worldwide demand for novel drug delivery systems (NDDS) is predicted to surge at a CAGR of 6.6% from 2022 to 2027. At present, the global novel drug delivery systems market enjoys a valuation of US$ 62.5 billion and is anticipated to climb to a market size of US$ 86 billion by the end of 2027. Oral drug delivery systems are projected to be extremely popular over the coming years owing to their ease of administration and the increasing patient-centric approach of the healthcare sector.

The offer in this portion accompanies many open doors including fabricating items, appropriation, retail, and showcasing administrations. Broad rounds of essential and far reaching optional exploration have been utilized by the examiners at Fact.MR to show up at different assessments and projections for Demand of Novel Drug Delivery Systems (NDDS) Market both at worldwide and provincial levels.

Download a Sample Copy of This Report:–
https://www.factmr.com/connectus/sample?flag=S&rep_id=7604?PJ 

The Novel Drug Delivery Systems (NDDS) market has witnessed significant growth as a pivotal component in the pharmaceutical industry, offering innovative approaches to drug administration. NDDS focuses on improving the efficacy, safety, and targeted delivery of therapeutic agents through advanced delivery mechanisms. The market's expansion is driven by the increasing demand for personalized medicine, advancements in drug formulation technologies, and the need for enhanced patient compliance. NDDS encompasses a wide array of delivery systems, including liposomes, nanoparticles, microparticles, and implants, each designed to address specific challenges in drug delivery and optimize therapeutic outcomes.

Key Market Drivers:

  • Enhanced Bioavailability and Therapeutic Efficacy: One of the primary drivers for the NDDS market is the quest for enhanced bioavailability and therapeutic efficacy of drugs. Traditional drug delivery systems often face challenges related to poor solubility, stability, and rapid clearance from the body. NDDS offers solutions such as nano-formulations and targeted delivery, improving drug absorption and overall therapeutic effectiveness.

  • Rise in Chronic Diseases and Targeted Therapies: The prevalence of chronic diseases, including cancer, diabetes, and cardiovascular conditions, has surged globally. NDDS plays a crucial role in the development of targeted therapies, delivering drugs precisely to affected tissues while minimizing systemic side effects. This approach aligns with the growing focus on precision medicine and personalized treatment strategies.

  • Advancements in Material Science and Nanotechnology: Technological advancements, particularly in material science and nanotechnology, have fueled innovation in NDDS. Nanoparticles and nanocarriers enable the controlled release of drugs, prolonged circulation in the bloodstream, and improved cellular uptake. These advancements contribute to the development of sophisticated drug delivery systems with superior therapeutic profiles.

Market Players: –

  • AstraZeneca PLC
  • Boston Scientific
  • Genzyme Co.
  • Bayer AG
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Tolmar
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Astellas
  • Aspen
  • Lupin
  • Breckenridge Pharmaceuticals
  • Shire
  • Galen
  • 3M Company
  • Merck & Co. Inc.
  • Teva Pharmaceuticals Industries Limited
  • Abbott Laboratories

Competitive Landscape

Key companies in the novel drug delivery systems market are expected to bolster their focus on the launch of new and modern drug delivery systems equipped with advanced technologies.

  • In June 2022, Gulfic Biosciences Ltd., an innovative pharmaceutical company, announced the launch of a new drug delivery system. The new drug delivery system technology was developed by Gulfic and its French counterpart at an affordable price. The new system is called Dual Chamber Bags (DCB).
  • In May 2022, Jabil Healthcare, a leading name in the healthcare industry, announced the launch of a reusable drug delivery device with a broader spectrum of applications. The Qfinity Autoinjector Platform will be available at lower costs than its market alternatives and is expected to further bolster the sustainability trend in the drug delivery industry owing to its reusable nature.

NDDS market players are also expected to eye acquisitions, partnerships, and mergers to enhance their business scope and expand their market presence across the world.

  • Bayer, a German biotechnology and pharmaceutical organization, in August 2021, announced the acquisition of Vividion Therapeutics to strengthen its portfolio of novel drug discovery platforms. The acquisition was valued at US$ 1.5 billion.
  • In June 2022, Accord Biopharma and EVERSANA partnered to launch the CAMCEVI (leuprolide) 42mg injection emulsion that is expected to be used for the treatment of prostate cancer in adults.

Key Segments of NDDS Industry Research

  • By Route :
    • Oral Drug Delivery Systems
    • Injectable Drug Delivery Systems
    • Pulmonary Drug Delivery Systems
    • Transdermal Drug Delivery Systems
    • Others
  • By Mode :
    • Targeted Drug Delivery Systems
    • Controlled Drug Delivery Systems
    • Modulated Drug Delivery Systems

Current Industry News (2023):

Several trends and developments may have shaped the NDDS market in 2023.

  • Focus on mRNA and Gene Delivery Systems: The industry may have witnessed a heightened focus on mRNA and gene delivery systems, especially with the emergence of mRNA-based COVID-19 vaccines. Advances in nucleic acid delivery technologies could lead to breakthroughs in gene therapies, opening new avenues for treating genetic disorders and various diseases at the molecular level.

  • Integration of Artificial Intelligence (AI) in Drug Design: The incorporation of artificial intelligence (AI) in drug design and formulation may have gained prominence. AI algorithms can analyze vast datasets to predict optimal drug delivery systems, accelerating the development process and enhancing the precision of NDDS.

  • Collaborations for Targeted Cancer Therapies: Collaborations between pharmaceutical companies and research institutions may have focused on developing targeted cancer therapies using NDDS. The ability to deliver anticancer agents specifically to tumor sites while sparing healthy tissues is a crucial area of exploration, and collaborative efforts could lead to breakthroughs in cancer treatment.

  • Advancements in Implantable Drug Delivery Devices: Implantable drug delivery devices may have seen advancements in terms of design, materials, and functionality. These devices offer sustained and localized drug release, improving patient compliance and reducing the frequency of administration. Ongoing innovations in implantable technologies could expand their applications across various therapeutic areas.